Arrowhead Pharmaceuticals
Stock Forecast, Prediction & Price Target
Arrowhead Pharmaceuticals (ARWR) stock Price Target by analysts
$42
Potential upside: 112.01%
Arrowhead Pharmaceuticals price prediction
What is Arrowhead Pharmaceuticals stock analysts` prediction?
Arrowhead Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Arrowhead Pharmaceuticals in the last 3 months, the avarage price target is $42, with a high forecast of $NaN. The average price target represents a 112.01% change from the last price of $19.81.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Arrowhead Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Arrowhead Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
William Pickering Bernstein | 0% 0/1 | 9 months ago | $24 21.15% upside | $25.81 | StreetInsider | Previous targets (0) |
Keay Nakae Loop Capital Markets | 0% 0/1 | 10 months ago | $60 202.87% upside | $12.9 | StreetInsider | Previous targets (0) |
David Lebowitz Citigroup | 0% 0/1 | about 1 year ago | $27 36.29% upside | $22.91 | StreetInsider | Previous targets (0) |
Patrick Trucchio H.C. Wainwright | 0% 0/2 | about 1 year ago | $60 202.87% upside | $25.57 | StreetInsider | Previous targets (1) |
Andrea Tan Goldman Sachs | 0% 0/1 | over 1 year ago | $31 56.48% upside | $25.29 | StreetInsider | Previous targets (0) |
Luca Issi RBC Capital | 0% 0/1 | over 1 year ago | $50 152.39% upside | $22.87 | StreetInsider | Previous targets (0) |
Unknown RBC Capital | N/A | over 2 years ago | $77 288.69% upside | $32.94 | Benzinga | N/A |
Unknown Piper Sandler | N/A | over 2 years ago | $52 162.49% upside | $33.51 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | almost 3 years ago | $90 354.31% upside | $31.52 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $37 86.77% upside | $28 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $31 56.48% upside | $28 | Benzinga | N/A |
Unknown Jefferies | N/A | almost 3 years ago | $75 278.59% upside | $29.99 | Benzinga | N/A |
Patrick Trucchio H.C. Wainwright | 0% 0/2 | about 3 years ago | $110 455.27% upside | $30.52 | Pulse 2.0 | Previous targets (1) |
Madhu Kumar Goldman Sachs | 0% 0/1 | over 3 years ago | $85 329.07% upside | $53.79 | Pulse 2.0 | Previous targets (0) |
Arrowhead Pharmaceuticals Financial Estimates
Arrowhead Pharmaceuticals Revenue Estimates
Arrowhead Pharmaceuticals EBITDA Estimates
Arrowhead Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 9/30/2022 | 9/30/2023 | 9/30/2024 | 9/30/2025 | 9/30/2026 | 9/30/2027 | 9/30/2028 |
Revenue
% change YoY
| $243.23M N/A | $240.73M -1.02% | $3.55M -98.52% | Avg: $160.56M Low: $13.82M High: $366.12M avg. 4421.78% | Avg: $233.15M Low: $39.03M High: $549.36M avg. 45.20% | Avg: $498.39M Low: $83.44M High: $1.17B avg. 113.76% | Avg: $865.01M Low: $144.82M High: $2.03B avg. 73.56% |
Net Income
% change YoY
| $-176.49M N/A | $-205.27M -16.30% | $-599.49M -192.04% | Avg: $-318.57M Low: $-547.62M High: $-1.06M avg. 46.85% | Avg: $-297.66M Low: $-403.79M High: $-16.01M avg. 6.56% | Avg: $-68.96M Low: $-190.54M High: $5.67M avg. 76.83% | Avg: $91.83M Low: $-7.56M High: $253.74M avg. 233.16% |
EBITDA
% change YoY
| $-178.50M N/A | $-175.67M 1.58% | $-561.51M -219.63% | Avg: $-100.12M Low: $-228.30M High: $-8.62M avg. 82.16% | Avg: $-145.38M Low: $-342.57M High: $-24.34M avg. -45.20% | Avg: $-310.78M Low: $-732.29M High: $-52.03M avg. -113.76% | Avg: $-539.40M Low: $-1.27B High: $-90.30M avg. -73.56% |
EPS
% change YoY
| -$1.67 N/A | -$1.91 -14.37% | -$5 -161.78% | Avg: -$2.69 Low: -$5.13 High: -$0.01 avg. 46.19% | Avg: -$2.35 Low: -$3.78 High: -$0.15 avg. 12.66% | Avg: -$0.65 Low: -$1.78 High: $0.05 avg. 72.50% | Avg: $0.86 Low: -$0.07 High: $2.38 avg. 233.16% |
Operating Expenses
% change YoY
| $421.73M N/A | $445.73M 5.69% | $604.63M 35.64% | Avg: $71.71M Low: $6.17M High: $163.51M avg. -88.13% | Avg: $104.12M Low: $17.43M High: $245.35M avg. 45.20% | Avg: $222.58M Low: $37.26M High: $524.47M avg. 113.76% | Avg: $386.32M Low: $64.67M High: $910.27M avg. 73.56% |
FAQ
What is Arrowhead Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 90.85% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is -547.62M, average is -318.57M and high is -1.06M.
What is Arrowhead Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1163.57% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $13.82M, average is $160.56M and high is $366.12M.
What is Arrowhead Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 91.13% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is -$5.13, average is -$2.69 and high is $-0.01.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Arrowhead Pharmaceuticals stock. The most successful analyst is William Pickering.